Vareniclin (parciální agonista alfa4beta2 nikotinových receptorů) v odvykání kouření
| Title in English | Varenicline (alfa4beta2 Nicotinic Receptor Partial Agonist) in Smoking Cessation |
|---|---|
| Authors | |
| Year of publication | 2007 |
| Type | Article in Periodical |
| Magazine / Source | Psychiatrie, časopis pro moderní psychiatrii |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | varenicline; smoking cessation; review |
| Description | Varenicline is an alfa4beta2 nicotinic receptor partial agonist; its mild stimulatory effect prevents incidence of withdrawal symptoms after nicotine withdrawal and its antagonizing effect blocks the effect of nicotine and release of dopamine in nucleus accumbens. Varenicline proved effective in smoking cessation in 6 controlled studies involving 4,912 chronic smokers. Judging from the abstinence rate, varenicline was significantly more efficient than both placebo and bupropione SR. The effect of varenicline was maintained throughout the period of 1 year in 22.44% of patients initially treated with this medication and continued to be significntly higher effective than in the group with initial placebo administration. The most afreqent undesirable effect was nausea. Varenicline is a promising smoking - cessation medication including patients with psychic disorders, a population with a higher smoking rate than the general population. |
| Related projects: |